Actinium Pharmaceuticals Faces Securities Lawsuit

Actinium Pharmaceuticals is facing a class action securities lawsuit initiated by Levi & Korsinsky. The lawsuit alleges that Actinium Pharmaceuticals made false and misleading statements to investors between October 31, 2022, and August 2, 2024. Specifically, the complaint claims that the company's data from the Phase 3 Sierra trial was unlikely to meet the United States — Food and Drug Administration's guidelines for the approval of its targeted radiotherapy, Iomab-B BLA. Furthermore, additional analyses provided by Actinium Pharmaceuticals to the United States — Food and Drug Administration to mitigate poor Overall Survival data were also deemed unlikely to satisfy the guidelines. As a result, the United States — Food and Drug Administration was expected to refuse to review or approve the Iomab-B BLA in its current form, rendering Actinium Pharmaceuticals' positive statements about its business and prospects materially misleading.